CN104561310A - 心源性猝死突变基因检测试剂盒 - Google Patents
心源性猝死突变基因检测试剂盒 Download PDFInfo
- Publication number
- CN104561310A CN104561310A CN201510003036.XA CN201510003036A CN104561310A CN 104561310 A CN104561310 A CN 104561310A CN 201510003036 A CN201510003036 A CN 201510003036A CN 104561310 A CN104561310 A CN 104561310A
- Authority
- CN
- China
- Prior art keywords
- seq
- gene
- sequence number
- primers
- shared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 72
- 206010049418 Sudden Cardiac Death Diseases 0.000 title claims abstract description 48
- 238000001514 detection method Methods 0.000 title claims abstract description 23
- 230000003321 amplification Effects 0.000 claims abstract description 78
- 238000011144 upstream manufacturing Methods 0.000 claims description 80
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 74
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 claims description 23
- 239000003471 mutagenic agent Substances 0.000 claims description 16
- 238000012360 testing method Methods 0.000 claims description 14
- 101150061256 KCNQ1 gene Proteins 0.000 claims description 10
- 102200004293 rs199472709 Human genes 0.000 claims description 10
- 102220006124 rs1042714 Human genes 0.000 claims description 9
- 102200096796 rs104894021 Human genes 0.000 claims description 9
- 102200150059 rs121434549 Human genes 0.000 claims description 9
- 102200109122 rs1805124 Human genes 0.000 claims description 9
- 101150033809 ADRB2 gene Proteins 0.000 claims description 7
- 101150063956 CASQ2 gene Proteins 0.000 claims description 6
- 101150083294 NUP155 gene Proteins 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 101150051809 KCNH2 gene Proteins 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000011535 reaction buffer Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 101150042605 RYR2 gene Proteins 0.000 claims description 4
- 102220017132 rs1805126 Human genes 0.000 claims description 4
- 210000002200 mouth mucosa Anatomy 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 101000741259 Homo sapiens Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein Proteins 0.000 claims 1
- 206010042434 Sudden death Diseases 0.000 abstract description 20
- 230000035772 mutation Effects 0.000 abstract description 2
- 238000003752 polymerase chain reaction Methods 0.000 abstract 4
- 239000011543 agarose gel Substances 0.000 abstract 1
- 238000001502 gel electrophoresis Methods 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000012163 sequencing technique Methods 0.000 description 27
- 230000003111 delayed effect Effects 0.000 description 13
- 101710200067 Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein Proteins 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000002107 myocardial effect Effects 0.000 description 11
- 102100037444 Potassium voltage-gated channel subfamily KQT member 1 Human genes 0.000 description 9
- 108010052164 Sodium Channels Proteins 0.000 description 9
- 102100038930 Carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase protein Human genes 0.000 description 8
- 101001108932 Homo sapiens Nuclear pore complex protein Nup155 Proteins 0.000 description 8
- 102100021512 Nuclear pore complex protein Nup155 Human genes 0.000 description 8
- 108010012219 Ryanodine Receptor Calcium Release Channel Proteins 0.000 description 8
- 102000018674 Sodium Channels Human genes 0.000 description 8
- 102100027198 Sodium channel protein type 5 subunit alpha Human genes 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 8
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 7
- 108010011185 KCNQ1 Potassium Channel Proteins 0.000 description 7
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 7
- 102000004912 RYR2 Human genes 0.000 description 7
- 108060007241 RYR2 Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 102100035602 Calsequestrin-2 Human genes 0.000 description 6
- 101000947118 Homo sapiens Calsequestrin-2 Proteins 0.000 description 6
- 229910001414 potassium ion Inorganic materials 0.000 description 6
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 5
- 230000001788 irregular Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108060003345 Adrenergic Receptor Proteins 0.000 description 4
- 102000017910 Adrenergic receptor Human genes 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 108010080437 Calsequestrin Proteins 0.000 description 4
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- 230000036982 action potential Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 101150030367 cls gene Proteins 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 210000004492 nuclear pore Anatomy 0.000 description 4
- 108020001213 potassium channel Proteins 0.000 description 4
- 230000002336 repolarization Effects 0.000 description 4
- 102000017919 ADRB2 Human genes 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 3
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002064 heart cell Anatomy 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000028161 membrane depolarization Effects 0.000 description 3
- 230000005405 multipole Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000007862 touchdown PCR Methods 0.000 description 3
- 101150028074 2 gene Proteins 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 2
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 2
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 2
- 102000000161 Calsequestrin Human genes 0.000 description 2
- 101001026226 Homo sapiens Potassium voltage-gated channel subfamily KQT member 1 Proteins 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 208000018452 Torsade de pointes Diseases 0.000 description 2
- 208000002363 Torsades de Pointes Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 101150087698 alpha gene Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 101150066838 12 gene Proteins 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 102000013975 Delayed Rectifier Potassium Channels Human genes 0.000 description 1
- 108010050556 Delayed Rectifier Potassium Channels Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101000974726 Homo sapiens Potassium voltage-gated channel subfamily E member 1 Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000163 Nuclear pore complex proteins Proteins 0.000 description 1
- 102000003789 Nuclear pore complex proteins Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 229930001406 Ryanodine Natural products 0.000 description 1
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 1
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 1
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000022900 cardiac muscle contraction Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 101150046383 gene 5 gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510003036.XA CN104561310B (zh) | 2015-01-04 | 2015-01-04 | 心源性猝死突变基因检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510003036.XA CN104561310B (zh) | 2015-01-04 | 2015-01-04 | 心源性猝死突变基因检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104561310A true CN104561310A (zh) | 2015-04-29 |
CN104561310B CN104561310B (zh) | 2019-02-05 |
Family
ID=53078384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510003036.XA Active CN104561310B (zh) | 2015-01-04 | 2015-01-04 | 心源性猝死突变基因检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104561310B (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105586405A (zh) * | 2016-01-15 | 2016-05-18 | 汪道文 | Adrb2,grk5基因多态性的检测方法和临床应用 |
WO2016206030A1 (zh) * | 2015-06-25 | 2016-12-29 | 谢小冬 | 一种分子标记物在猝死发生早期筛查中的用途 |
CN106868126A (zh) * | 2017-02-20 | 2017-06-20 | 深圳美因临床检验所有限公司 | 荧光定量pcr检测试剂盒及检测方法 |
CN108517357A (zh) * | 2018-03-12 | 2018-09-11 | 山西医科大学 | 一种检测心源性猝死相关scn5a基因上心源性猝死相关snp的试剂盒及其检测方法 |
CN109371125A (zh) * | 2018-12-31 | 2019-02-22 | 山西医科大学 | 基于kcnq1的心源性猝死相关snp检测试剂盒及检测方法 |
CN112111572A (zh) * | 2020-10-12 | 2020-12-22 | 苏州大学 | 基于stat5a基因插入缺失多态性位点的心源性猝死易感性检测试剂盒 |
WO2022073259A1 (zh) * | 2020-10-10 | 2022-04-14 | 苏州大学 | 基于cox10基因插入缺失多态性位点的心源性猝死易感性检测试剂盒 |
WO2022077540A1 (zh) * | 2020-10-12 | 2022-04-21 | 苏州大学 | 基于stim1基因插入缺失多态性位点的心源性猝死易感性检测试剂盒 |
CN116426632A (zh) * | 2023-03-30 | 2023-07-14 | 苏州大学 | Ltbp4基因多态性位点检测心源性猝死的分子标记及试剂盒 |
CN118006751A (zh) * | 2023-11-07 | 2024-05-10 | 北京普利莱基因技术有限公司 | 心源性猝死基因突变检测引物组、试剂盒、方法及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006063582A2 (de) * | 2004-12-18 | 2006-06-22 | Hanns-Georg Klein | Verfahren zum nachweis von herzerkrankungen |
WO2006131528A2 (en) * | 2005-06-07 | 2006-12-14 | Fondazione Salvatore Maugeri Clinica Del Lavoro E Della Riabilitazione I.R.C.C.S. | Mutations associated with the long qt syndrome and diagnostic use thereof |
CN101580835A (zh) * | 2008-05-15 | 2009-11-18 | 复旦大学附属中山医院 | 一种心脏钠通道基因scn5a新突变体及其检测方法 |
US8658358B1 (en) * | 2009-04-21 | 2014-02-25 | Transgenomic, Inc. | Mutations associated with long QT syndrome |
CN103757091A (zh) * | 2013-09-13 | 2014-04-30 | 广州市体育科学研究所 | 心源性猝死快速基因检测试剂盒及检测方法 |
-
2015
- 2015-01-04 CN CN201510003036.XA patent/CN104561310B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006063582A2 (de) * | 2004-12-18 | 2006-06-22 | Hanns-Georg Klein | Verfahren zum nachweis von herzerkrankungen |
WO2006131528A2 (en) * | 2005-06-07 | 2006-12-14 | Fondazione Salvatore Maugeri Clinica Del Lavoro E Della Riabilitazione I.R.C.C.S. | Mutations associated with the long qt syndrome and diagnostic use thereof |
CN101580835A (zh) * | 2008-05-15 | 2009-11-18 | 复旦大学附属中山医院 | 一种心脏钠通道基因scn5a新突变体及其检测方法 |
US8658358B1 (en) * | 2009-04-21 | 2014-02-25 | Transgenomic, Inc. | Mutations associated with long QT syndrome |
CN103757091A (zh) * | 2013-09-13 | 2014-04-30 | 广州市体育科学研究所 | 心源性猝死快速基因检测试剂盒及检测方法 |
Non-Patent Citations (4)
Title |
---|
ANNUKKA LAHTINEN: "GENETIC VARIANTS PREDISPOSING TO CARDIAC ARRHYTHMIA DISORDERS AND SUDDEN CARDIAC DEATH", 《HELSINKI UNIVERSITY BIOMEDICAL DISSERTATIONS》 * |
DANIEL C. BARTOS等: "A KCNQ1 Mutation Causes a High Penetrance for Familial Atrial Fibrillation", 《J CARDIOVASC ELECTROPHYSIOL.》 * |
JIANDING CHENG等: "Sudden unexplained nocturnal death syndrome in southern China: epidemiological survey and SCN5A gene screening", 《AM J FORENSIC MED PATHOL.》 * |
YUQIN RAN等: "Common RyR2 variants associate with ventricular arrhythmias and sudden cardiac death in chronic heart failure", 《CLINICAL SCIENCE》 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016206030A1 (zh) * | 2015-06-25 | 2016-12-29 | 谢小冬 | 一种分子标记物在猝死发生早期筛查中的用途 |
CN105586405A (zh) * | 2016-01-15 | 2016-05-18 | 汪道文 | Adrb2,grk5基因多态性的检测方法和临床应用 |
CN106868126B (zh) * | 2017-02-20 | 2020-06-19 | 深圳美因医学检验实验室 | 荧光定量pcr检测试剂盒及检测方法 |
WO2018149264A1 (zh) * | 2017-02-20 | 2018-08-23 | 深圳美因医学检验实验室 | 荧光定量pcr检测试剂盒及检测方法 |
CN106868126A (zh) * | 2017-02-20 | 2017-06-20 | 深圳美因临床检验所有限公司 | 荧光定量pcr检测试剂盒及检测方法 |
CN108517357A (zh) * | 2018-03-12 | 2018-09-11 | 山西医科大学 | 一种检测心源性猝死相关scn5a基因上心源性猝死相关snp的试剂盒及其检测方法 |
CN108517357B (zh) * | 2018-03-12 | 2022-05-24 | 山西医科大学 | 一种检测心源性猝死相关scn5a基因上心源性猝死相关snp的试剂盒及其检测方法 |
CN109371125A (zh) * | 2018-12-31 | 2019-02-22 | 山西医科大学 | 基于kcnq1的心源性猝死相关snp检测试剂盒及检测方法 |
WO2022073259A1 (zh) * | 2020-10-10 | 2022-04-14 | 苏州大学 | 基于cox10基因插入缺失多态性位点的心源性猝死易感性检测试剂盒 |
CN112111572A (zh) * | 2020-10-12 | 2020-12-22 | 苏州大学 | 基于stat5a基因插入缺失多态性位点的心源性猝死易感性检测试剂盒 |
CN112111572B (zh) * | 2020-10-12 | 2021-10-08 | 苏州大学 | 基于stat5a基因插入缺失多态性位点的心源性猝死易感性检测试剂盒 |
WO2022077540A1 (zh) * | 2020-10-12 | 2022-04-21 | 苏州大学 | 基于stim1基因插入缺失多态性位点的心源性猝死易感性检测试剂盒 |
WO2022077539A1 (zh) * | 2020-10-12 | 2022-04-21 | 苏州大学 | 基于stat5a基因插入缺失多态性位点的心源性猝死易感性检测试剂盒 |
CN116426632A (zh) * | 2023-03-30 | 2023-07-14 | 苏州大学 | Ltbp4基因多态性位点检测心源性猝死的分子标记及试剂盒 |
CN118006751A (zh) * | 2023-11-07 | 2024-05-10 | 北京普利莱基因技术有限公司 | 心源性猝死基因突变检测引物组、试剂盒、方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104561310B (zh) | 2019-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104561310A (zh) | 心源性猝死突变基因检测试剂盒 | |
Keating et al. | Molecular and cellular mechanisms of cardiac arrhythmias | |
Li et al. | Mutations of the SCN4B-encoded sodium channel β4 subunit in familial atrial fibrillation | |
Goldenberg et al. | Clinical course and risk stratification of patients affected with the Jervell and Lange‐Nielsen syndrome | |
Imberti et al. | Clinical challenges in catecholaminergic polymorphic ventricular tachycardia | |
Berthome et al. | Clinical presentation and follow-up of women affected by Brugada syndrome | |
Moss et al. | Congenital long QT syndrome: considerations for primary care physicians | |
Mascia et al. | The long‐QT syndrome and exercise practice: the never‐ending debate | |
Kanters et al. | Flecainide provocation reveals concealed brugada syndrome in a long QT syndrome family with a novel L1786Q mutation in SCN5A | |
Priori et al. | Inherited arrhythmia syndromes: applying the molecular biology and genetic to the clinical management | |
CN107858423A (zh) | 用于诊断/预测心源性猝死的试剂盒 | |
CN102115787B (zh) | 一种微小rna及其反义核酸在制备诊断、预防、治疗和/或预后评估心脏疾病的试剂盒或药物中的用途 | |
Miller et al. | Sodium channels, cardiac arrhythmia, and therapeutic strategy | |
Wang | Congenital long QT syndrome: 50 years of electrophysiological research from cell to bedside | |
CN116785309A (zh) | 环状rna在制备用于预防和/或治疗缺血性卒中药物中的应用 | |
Lane et al. | Happiness and stress alter susceptibility to cardiac events in Long QT Syndrome | |
Fuku et al. | Association of mitochondrial DNA polymorphisms and/or haplogroups with elite Japanese athlete status | |
Oka et al. | Atrioventricular block-induced Torsades de Pointes with clinical and molecular backgrounds similar to congenital long QT syndrome | |
US11795509B2 (en) | Screening kit for paroxysmal supraventricular tachycardia | |
Carboni et al. | Aberrant splicing in the LMNA gene caused by a novel mutation on the polypyrimidine tract of intron 5 | |
AlSenaidi et al. | Long QT syndrome, cardiovascular anomaly and findings in ECG-guided genetic testing | |
CN110904210B (zh) | 一种常染色体显性Dnajc17基因突变体及其应用和诊断试剂盒、诊断基因芯片 | |
Phillips et al. | Evaluation and treatment of pediatric patients with congenital or acquired long QT interval syndromes | |
Moric et al. | Expression of genes KCNQ1 and HERG encoding potassium ion channels Ik r, Ik s in long QT syndrome | |
Kılıç et al. | Jervell and Lange-Nielsen syndrome with homozygous missense mutation of the KCNQ1 gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20181219 Address after: 710075 Room 109, Pioneer Building, No. 2, High-tech Five Road, Xi'an High-tech Zone, Shaanxi Province Applicant after: Xi'an Bestedit Biomedical Services Co., Ltd. Address before: 710061 No. 29 Chang'an South Road, Yanta District, Xi'an City, Shaanxi Province Applicant before: CHAOYING SHAANXI INSTITUTE OF CLINICAL PATHOLOGY |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210602 Address after: 710000 No.5-2, north section of Chang'an Road, Beilin District, Xi'an City, Shaanxi Province Patentee after: Xie Yi Address before: 710075 Room 109, Pioneer Building, No. 2, High-tech Five Road, Xi'an High-tech Zone, Shaanxi Province Patentee before: Xi'an Bestedit Biomedical Services Co.,Ltd. |
|
TR01 | Transfer of patent right |